Oculis (NASDAQ:OCS) Sees Large Volume Increase - Time to Buy?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw unusually-high trading volume on Friday . Approximately 24,743 shares changed hands during mid-day trading, a decline of 43% from the previous session's volume of 43,667 shares.The stock last traded at $17.97 and had previously closed at $17.89.

Wall Street Analyst Weigh In

OCS has been the topic of a number of analyst reports. Chardan Capital reiterated a "buy" rating and issued a $28.00 price objective on shares of Oculis in a research report on Thursday, April 17th. Robert W. Baird lifted their price objective on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th. Finally, HC Wainwright raised their target price on Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, April 17th.

Oculis Trading Up 5.1 %

The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $18.39 and a 200 day simple moving average of $18.19. The company has a market cap of $779.80 million, a price-to-earnings ratio of -9.25 and a beta of 0.19.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, equities analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bellevue Group AG acquired a new position in shares of Oculis during the 4th quarter worth $170,000. XTX Topco Ltd purchased a new stake in Oculis during the 4th quarter worth about $225,000. Geode Capital Management LLC increased its position in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Oculis during the 4th quarter worth about $389,000. Finally, Bank of America Corp DE increased its position in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.